InvestorsHub Logo
Followers 2
Posts 96
Boards Moderated 0
Alias Born 10/16/2010

Re: None

Tuesday, 04/19/2016 7:53:13 PM

Tuesday, April 19, 2016 7:53:13 PM

Post# of 23979
FLKS news... 4:15 pm Flex Pharma announces results from its recently completed study in nocturnal leg cramps; statistically significant effects demonstrated (FLKS) :

Co announces that results from its recently completed study in nocturnal leg cramps will be presented later today at the American Academy of Neurology 68th Annual Meeting in Vancouver.

The extract formulation resulted in a median reduction of 6 total cramps over a 2-week period vs. 4 for placebo (p
The positive effects were seen across a broad range of enrolled subjects; in addition, a subset of patients showed pronounced benefit.
The magnitude of efficacy in this study on reduction in muscle cramps appears similar to published "Class 1 level" quinine efficacy studies.
Statistically significant effects were also demonstrated on these key endpoints: the physician-rated Clinical Global Impression of Change (CGI-C) (p
Additionally, the product appeared to be safe and well-tolerated and there were no serious adverse events reported.
Co is moving forward to initiate studies with a single molecule TRP activator in NLC, MS and ALS this year.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.